Pitcairn Co. Purchases New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Pitcairn Co. purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 52,575 shares of the company's stock, valued at approximately $947,000.

Other institutional investors have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC increased its position in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock valued at $2,025,000 after acquiring an additional 805 shares during the last quarter. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after purchasing an additional 980 shares during the last quarter. Signaturefd LLC lifted its stake in Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company's stock worth $137,000 after purchasing an additional 1,094 shares during the last quarter. QRG Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 0.8% during the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company's stock valued at $2,355,000 after buying an additional 1,191 shares during the period. Finally, United Services Automobile Association grew its stake in shares of Teva Pharmaceutical Industries by 3.1% during the second quarter. United Services Automobile Association now owns 41,159 shares of the company's stock valued at $669,000 after buying an additional 1,249 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on TEVA. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, October 21st. Finally, Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Down 2.5 %

NYSE TEVA traded down $0.43 on Monday, hitting $16.69. The stock had a trading volume of 11,620,606 shares, compared to its average volume of 9,232,298. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The business's fifty day moving average price is $17.67 and its 200 day moving average price is $17.35. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The stock has a market cap of $18.91 billion, a price-to-earnings ratio of -19.87, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company's stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.